S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
S&P 500   3,821.35
DOW   31,802.44
QQQ   299.94
pixel
Log in
NASDAQ:RAPT

RAPT Therapeutics Stock Forecast, Price & News

$17.16
+0.25 (+1.48 %)
(As of 03/8/2021 12:00 AM ET)
Add
Compare
Today's Range
$16.51
Now: $17.16
$17.94
50-Day Range
$16.00
MA: $20.00
$21.95
52-Week Range
$10.52
Now: $17.16
$41.86
Volume228,264 shs
Average Volume144,654 shs
Market Capitalization$421.36 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.03
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics logo

Headlines

Is RAPT A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Monday 11/23 Insider Buying Report: RAPT, ZGNX
November 23, 2020 |  nasdaq.com
RAPT Therapeutics EPS misses by $0.02, beats on revenue
November 16, 2020 |  seekingalpha.com
This Day That Year: RAPT Therapeutics (RAPT)
October 30, 2020 |  nasdaq.com
RAPT Therapeutics (RAPT) Catches Eye: Stock Jumps 6.1%
September 3, 2020 |  finance.yahoo.com
RAPT Therapeutics EPS beats by $0.07, beats on revenue
August 13, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RAPT
CUSIPN/A
CIKN/A
Phone650-489-9000
Employees71
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$3.35 per share

Profitability

Net Income$-43,000,000.00

Miscellaneous

Market Cap$421.36 million
Next Earnings Date3/29/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

385th out of 1,971 stocks

Pharmaceutical Preparations Industry

186th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$17.16
+0.25 (+1.48 %)
(As of 03/8/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RAPT News and Ratings via Email

Sign-up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RAPT Therapeutics (NASDAQ:RAPT) Frequently Asked Questions

Is RAPT Therapeutics a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for RAPT Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RAPT Therapeutics stock.
View analyst ratings for RAPT Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than RAPT Therapeutics?

Wall Street analysts have given RAPT Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RAPT Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting RAPT Therapeutics?

RAPT Therapeutics saw a drop in short interest during the month of January. As of January 29th, there was short interest totaling 814,500 shares, a drop of 28.6% from the January 14th total of 1,140,000 shares. Based on an average daily trading volume, of 427,300 shares, the days-to-cover ratio is presently 1.9 days. Approximately 5.2% of the shares of the stock are sold short.
View RAPT Therapeutics' Short Interest
.

When is RAPT Therapeutics' next earnings date?

RAPT Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 29th 2021.
View our earnings forecast for RAPT Therapeutics
.

How were RAPT Therapeutics' earnings last quarter?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) announced its quarterly earnings data on Sunday, November, 15th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.56) by $0.04. The firm earned $1.53 million during the quarter, compared to analysts' expectations of $2.50 million.
View RAPT Therapeutics' earnings history
.

How has RAPT Therapeutics' stock been impacted by COVID-19?

RAPT Therapeutics' stock was trading at $15.73 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, RAPT shares have increased by 9.1% and is now trading at $17.16.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RAPT?

5 equities research analysts have issued 12 month target prices for RAPT Therapeutics' shares. Their forecasts range from $30.00 to $51.00. On average, they anticipate RAPT Therapeutics' stock price to reach $40.80 in the next twelve months. This suggests a possible upside of 137.8% from the stock's current price.
View analysts' price targets for RAPT Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are RAPT Therapeutics' key executives?

RAPT Therapeutics' management team includes the following people:
  • Dr. Brian Russell Wong, CEO, Pres & Director (Age 49, Pay $912.2k)
  • Mr. Rodney K. B. Young, CFO, Principal Accounting Officer & Sec. (Age 58, Pay $132.08k)
  • Dr. Dirk G. Brockstedt Ph.D., Chief Scientific Officer (Age 52, Pay $427.77k)
  • Steve Young Ph.D., VP of Technology
  • Ms. Phyllis Loud Gray, VP of HR
  • Dr. Paul Kassner, Sr. VP of Quantitative & Computational Biology (Age 54)
  • Dr. David Wustrow, Sr. VP of Drug Discovery & Preclinical Devel. (Age 62)
  • Dr. William Ho, Chief Medical Officer (Age 56)

What is Brian Wong's approval rating as RAPT Therapeutics' CEO?

8 employees have rated RAPT Therapeutics CEO Brian Wong on Glassdoor.com. Brian Wong has an approval rating of 100% among RAPT Therapeutics' employees. This puts Brian Wong in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of RAPT Therapeutics' key competitors?

What other stocks do shareholders of RAPT Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RAPT Therapeutics investors own include NVIDIA (NVDA), The Boeing (BA), Slack Technologies (WORK), Overstock.com (OSTK), salesforce.com (CRM), Enphase Energy (ENPH), Inovio Pharmaceuticals (INO), Livongo Health (LVGO), Mastercard (MA) and QUALCOMM (QCOM).

When did RAPT Therapeutics IPO?

(RAPT) raised $39 million in an initial public offering (IPO) on Thursday, October 31st 2019. The company issued 3,000,000 shares at $12.00-$14.00 per share. BMO Capital Markets, Wells Fargo Securities and UBS Investment Bank served as the underwriters for the IPO.

What is RAPT Therapeutics' stock symbol?

RAPT Therapeutics trades on the NASDAQ under the ticker symbol "RAPT."

Who are RAPT Therapeutics' major shareholders?

RAPT Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.53%), BlackRock Inc. (5.64%), Regents of The University of California (4.57%), Acuta Capital Partners LLC (0.85%), Northern Trust Corp (0.61%) and Charles Schwab Investment Management Inc. (0.27%). Company insiders that own RAPT Therapeutics stock include Brian Russell Wong, Dirk G Brockstedt, Group Ii Lp Column, Karen C Lam, Michael F Giordano, Peter Svennilson, Wendye Robbins and William Ho.
View institutional ownership trends for RAPT Therapeutics
.

Which major investors are selling RAPT Therapeutics stock?

RAPT stock was sold by a variety of institutional investors in the last quarter, including Regents of The University of California, Price T Rowe Associates Inc. MD, Acuta Capital Partners LLC, Wells Fargo & Company MN, Virtus ETF Advisers LLC, and State of Wisconsin Investment Board. Company insiders that have sold RAPT Therapeutics company stock in the last year include Brian Russell Wong, Dirk G Brockstedt, Karen C Lam, Michael F Giordano, Peter Svennilson, and William Ho.
View insider buying and selling activity for RAPT Therapeutics
or view top insider-selling stocks.

Which major investors are buying RAPT Therapeutics stock?

RAPT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Swiss National Bank, Squarepoint Ops LLC, Voloridge Investment Management LLC, Bank of New York Mellon Corp, QS Investors LLC, William Marsh Rice University, and Renaissance Technologies LLC. Company insiders that have bought RAPT Therapeutics stock in the last two years include Brian Russell Wong, Group Ii Lp Column, and Wendye Robbins.
View insider buying and selling activity for RAPT Therapeutics
or or view top insider-buying stocks.

How do I buy shares of RAPT Therapeutics?

Shares of RAPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RAPT Therapeutics' stock price today?

One share of RAPT stock can currently be purchased for approximately $17.16.

How much money does RAPT Therapeutics make?

RAPT Therapeutics has a market capitalization of $421.36 million. The company earns $-43,000,000.00 in net income (profit) each year or ($9.89) on an earnings per share basis.

How many employees does RAPT Therapeutics have?

RAPT Therapeutics employs 71 workers across the globe.

What is RAPT Therapeutics' official website?

The official website for RAPT Therapeutics is www.rapt.com.

Where are RAPT Therapeutics' headquarters?

RAPT Therapeutics is headquartered at 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact RAPT Therapeutics?

RAPT Therapeutics' mailing address is 561 ECCLES AVENUE, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-489-9000 or via email at [email protected]


This page was last updated on 3/9/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.